Guilherme S. Lira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guilherme S. Lira has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Terezinha Marta Pereira Pinto Castiñeiras
Núcleo de Enfrentamento e Estudos de Doenças Infecciosas Emergentes e Reemergentes, Universidade Federal do Rio de Janeiro
4 shared publications - Andre Macedo Vale
Laboratório de Biologia de Linfócitos, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro
3 shared publications - Luciana Conde
Yale University School of Medicine 1 Department of Immunobiology New Haven, CT
3 shared publications Luiza M. Higa
Núcleo de Enfrentamento e Estudos de Doenças Infecciosas Emergentes e Reemergentes, Universidade Federal do Rio de Janeiro
3 shared publications- Amilcar Tanuri
Federal University of Rio de Janeiro
2 shared publications - Carolina Lucas
Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA
2 shared publications
Latest Publications
- Open Access
- 4 November 2025
- Published by American Society for Microbiology in ASM Case Reports
- Vol. 1 (6)
Atypical presentation of occupational mpox: a case report from Brazil
Background: After decades of circulating predominantly in Africa, mpox caused a public health emergency of international concern between 2022 and 2023. Even outside of the epidemic period, the virus still circulates, with threats of reemergence, and different clinical presentations must be brought to attention for optimal surveillance. Case Summary: We report a case of monkeypox virus (MPXV) infection in a previously healthy physician with an atypical clinical presentation and a single identified exposure. Diagnosis was confirmed by PCR. Viral isolation was employed to reinforce diagnosis. Plaque reduction neutralization assays and semiquantitative ELISA were used to evaluate the antibody response. Conclusion: Our report has two main messages: atypical symptoms of mpox can hinder diagnosis, making adequate suspicion and testing fundamental; and the risk of occupational exposure must be considered when designing policies for healthcare workers.
- 4 November 2025
- Published by American Society for Microbiology in ASM Case Reports
- Vol. 1 (6)
Open AccessAtypical presentation of occupational mpox: a case report from Brazil
Background: After decades of circulating predominantly in Africa, mpox caused a public health emergency of international concern between 2022 and 2023. Even outside of the epidemic period, the virus still circulates, with threats of reemergence, and different clinical presentations must be brought to attention for optimal surveillance. Case Summary: We report a case of monkeypox virus (MPXV) infection in a previously healthy physician with an atypical clinical presentation and a single identified exposure. Diagnosis was confirmed by PCR. Viral isolation was employed to reinforce diagnosis. Plaque reduction neutralization assays and semiquantitative ELISA were used to evaluate the antibody response. Conclusion: Our report has two main messages: atypical symptoms of mpox can hinder diagnosis, making adequate suspicion and testing fundamental; and the risk of occupational exposure must be considered when designing policies for healthcare workers.
- Top Cited PapersOpen Access
- 28 April 2025
- Published by Elsevier in The Lancet Microbe
- Vol. 6 (7) , 101098
The impact of orthopoxvirus vaccination and Mpox infection on cross-protective immunity: a multicohort observational study
- 28 April 2025
- Published by Elsevier in The Lancet Microbe
- Vol. 6 (7) , 101098
Top Cited PapersOpen AccessThe impact of orthopoxvirus vaccination and Mpox infection on cross-protective immunity: a multicohort observational study
- 24 April 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (5) , e29621
Mpox outbreak in Rio de Janeiro, Brazil: A translational approach
Mpox is a zoonotic disease historically reported in Africa. Since 2003, limited outbreaks have occurred outside Africa. In 2022, the global spread of cases with sustained interhuman transmission and unusual disease features raised public health concerns. We explore the mpox outbreak in Rio de Janeiro (RJ) state, Brazil, in an observational study of mpox‐suspected cases from June to December 2022. Data collection relied on a public healthcare notification form. Diagnosis was determined by MPXV‐PCR. In 46 confirmed cases, anti‐OPXV IgG was determined by ELISA, and seven MPXV genomes were sequenced. A total of 3095 cases were included, 816 (26.3%) with positive MPXV‐PCR results. Most positive cases were men in their 30 s and MSM. A total of 285 (34.9%) MPXV‐PCR+ patients live with HIV. Eight were coinfected with varicella‐zoster virus. Anogenital lesions and adenomegaly were associated with the diagnosis of mpox. Females and individuals under 18 represented 9.4% and 5.4% of all confirmed cases, respectively, showing higher PCR cycle threshold (Ct) values and fewer anogenital lesions compared to adult men. Anti‐OPXV IgG was detected in 29/46 (63.0%) patients. All analyzed sequences belonged to clade IIb. In RJ state, mpox presented a diverse clinical picture, represented mainly by mild cases with low complication rates and prominent genital involvement. The incidence in females and children was higher than usually reported. The observation of a bimodal distribution of Ct values, with few positive results, may suggest the need to review the diagnostic criteria in these groups.
- 24 April 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (5) , e29621
Mpox outbreak in Rio de Janeiro, Brazil: A translational approach
Mpox is a zoonotic disease historically reported in Africa. Since 2003, limited outbreaks have occurred outside Africa. In 2022, the global spread of cases with sustained interhuman transmission and unusual disease features raised public health concerns. We explore the mpox outbreak in Rio de Janeiro (RJ) state, Brazil, in an observational study of mpox‐suspected cases from June to December 2022. Data collection relied on a public healthcare notification form. Diagnosis was determined by MPXV‐PCR. In 46 confirmed cases, anti‐OPXV IgG was determined by ELISA, and seven MPXV genomes were sequenced. A total of 3095 cases were included, 816 (26.3%) with positive MPXV‐PCR results. Most positive cases were men in their 30 s and MSM. A total of 285 (34.9%) MPXV‐PCR+ patients live with HIV. Eight were coinfected with varicella‐zoster virus. Anogenital lesions and adenomegaly were associated with the diagnosis of mpox. Females and individuals under 18 represented 9.4% and 5.4% of all confirmed cases, respectively, showing higher PCR cycle threshold (Ct) values and fewer anogenital lesions compared to adult men. Anti‐OPXV IgG was detected in 29/46 (63.0%) patients. All analyzed sequences belonged to clade IIb. In RJ state, mpox presented a diverse clinical picture, represented mainly by mild cases with low complication rates and prominent genital involvement. The incidence in females and children was higher than usually reported. The observation of a bimodal distribution of Ct values, with few positive results, may suggest the need to review the diagnostic criteria in these groups.
- Open Access
The impact of antigenic distance on Orthopoxvirus Vaccination and Mpox Infection for cross-protective immunity
Immunological memory mediates rapid protection following infection or vaccination including heterologous exposure. However, cross-reactive memory responses in humans remain poorly characterized. We explored the longevity and specificity of cross-protective responses to orthopoxviruses through smallpox vaccination and Mpox virus (MPXV) infection. Smallpox vaccination using Vaccinia virus (VACV)-based vaccines provides a unique opportunity to study long-term cross-protective immunity without antigen re-exposure. We assessed systemic and mucosal responses in four human cohorts, including first-(Dryvax) and/or third-generation (JYNNEOS) smallpox vaccine recipients (vaccinated 1 week-80 years ago), along with Mpox-infected individuals. First-and third-generation smallpox vaccines elicited strong VACV- and MPXV-specific antibodies. VACV-neutralizing antibodies persisted for decades in first-generation vaccine recipients and were further enhanced after JYNNEOS vaccination. However, despite the high levels of anti-MPXV-specific antibodies in the plasma, cross-neutralization activity was directly correlated with the antigenic distance. Higher neutralization was observed for the cowpox virus (CWPXV) than for MPXV, which showed lower antigenic conservation with VACV. Similarly, Mpox-infected patients had lower neutralization titers for VACV than for CWPXV. Individuals who received vaccination boosters showed more robust, diverse, and prolonged cross-neutralizing responses. Long-term memory analysis revealed an increase in neutralization capacity for VACV over decades, with 80-years-old displaying the most robust humoral response, although this trend was not observed for cross-reactive antigens. Finally, T-cell reactivity to VACV and MPXV epitopes was detected decades post-vaccination, suggesting a role of long-lasting cross-reactive T-cell memory responses in vaccine efficacy. Our findings underscore the pivotal influence of antigenic distance on vaccine effectiveness with implications for cross-protective vaccine design.
Open AccessThe impact of antigenic distance on Orthopoxvirus Vaccination and Mpox Infection for cross-protective immunity
Immunological memory mediates rapid protection following infection or vaccination including heterologous exposure. However, cross-reactive memory responses in humans remain poorly characterized. We explored the longevity and specificity of cross-protective responses to orthopoxviruses through smallpox vaccination and Mpox virus (MPXV) infection. Smallpox vaccination using Vaccinia virus (VACV)-based vaccines provides a unique opportunity to study long-term cross-protective immunity without antigen re-exposure. We assessed systemic and mucosal responses in four human cohorts, including first-(Dryvax) and/or third-generation (JYNNEOS) smallpox vaccine recipients (vaccinated 1 week-80 years ago), along with Mpox-infected individuals. First-and third-generation smallpox vaccines elicited strong VACV- and MPXV-specific antibodies. VACV-neutralizing antibodies persisted for decades in first-generation vaccine recipients and were further enhanced after JYNNEOS vaccination. However, despite the high levels of anti-MPXV-specific antibodies in the plasma, cross-neutralization activity was directly correlated with the antigenic distance. Higher neutralization was observed for the cowpox virus (CWPXV) than for MPXV, which showed lower antigenic conservation with VACV. Similarly, Mpox-infected patients had lower neutralization titers for VACV than for CWPXV. Individuals who received vaccination boosters showed more robust, diverse, and prolonged cross-neutralizing responses. Long-term memory analysis revealed an increase in neutralization capacity for VACV over decades, with 80-years-old displaying the most robust humoral response, although this trend was not observed for cross-reactive antigens. Finally, T-cell reactivity to VACV and MPXV epitopes was detected decades post-vaccination, suggesting a role of long-lasting cross-reactive T-cell memory responses in vaccine efficacy. Our findings underscore the pivotal influence of antigenic distance on vaccine effectiveness with implications for cross-protective vaccine design.
- Open Access
- 7 July 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (9)
Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a global problem in part because of the emergence of variants of concern that evade neutralization by antibodies elicited by prior infection or vaccination. Here we report on human neutralizing antibody and memory responses to the Gamma variant in a cohort of hospitalized individuals. Plasma from infected individuals potently neutralized viruses pseudotyped with Gamma SARS-CoV-2 spike protein, but neutralizing activity against Wuhan-Hu-1-1, Beta, Delta, or Omicron was significantly lower. Monoclonal antibodies from memory B cells also neutralized Gamma and Beta pseudoviruses more effectively than Wuhan-Hu-1. 69% and 34% of Gamma-neutralizing antibodies failed to neutralize Delta or Wuhan-Hu-1. Although Class 1 and 2 antibodies dominate the response to Wuhan-Hu-1 or Beta, 54% of antibodies elicited by Gamma infection recognized Class 3 epitopes. The results have implications for variant-specific vaccines and infections, suggesting that exposure to variants generally provides more limited protection to other variants.
- 7 July 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (9)
Open AccessPlasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a global problem in part because of the emergence of variants of concern that evade neutralization by antibodies elicited by prior infection or vaccination. Here we report on human neutralizing antibody and memory responses to the Gamma variant in a cohort of hospitalized individuals. Plasma from infected individuals potently neutralized viruses pseudotyped with Gamma SARS-CoV-2 spike protein, but neutralizing activity against Wuhan-Hu-1-1, Beta, Delta, or Omicron was significantly lower. Monoclonal antibodies from memory B cells also neutralized Gamma and Beta pseudoviruses more effectively than Wuhan-Hu-1. 69% and 34% of Gamma-neutralizing antibodies failed to neutralize Delta or Wuhan-Hu-1. Although Class 1 and 2 antibodies dominate the response to Wuhan-Hu-1 or Beta, 54% of antibodies elicited by Gamma infection recognized Class 3 epitopes. The results have implications for variant-specific vaccines and infections, suggesting that exposure to variants generally provides more limited protection to other variants.